A recent study has shown that longer treatment (72h) with higher doses of omoMYC (20 μM) reduces proliferationof the MYCN-amplified neuroblastoma cell lines Kellyand IMR32. Further investigations areneeded to elucidate the underlying mechanism of this cell type specificityand to identify factors that predict treatment response. Here, MYCN is linked to neuroblastoma.